Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

n.v. organon* - ezetimibum inn - tafla - 10 mg

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum acetat - stungulyf, dreifa - 40 mg/ml

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 125 mg

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 500 mg

Evropská unie - islandština - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - blæðandi hiti, ebóla - bóluefni - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Evropská unie - islandština - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - skal læknir hafa blöðrum bólgur veira (álag indiana) með eyðingu umslagið glýkóprótein, komi með zaire ebolavirus (álag kikwit 1995) yfirborðið glýkóprótein - blæðandi hiti, ebóla - bóluefni - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. notkun ervebo ætti að vera í samræmi við opinbera tillögur.

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 150 mg

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 300 mg

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 75 mg